Serum taurine as a marker of endometrial cancer

Open Women's Health Journal

Volumn 5, Issue 1, 2011, Pages 1-6

  El Agouza, Ibraheem M A ^a   El Nashar, Dalia E ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b NATIONAL CENTER FOR RADIATION RESEARCH AND TECHNOLOGY   (Egypt)

Author keywords

Ca 125; Endometrial cancer; Serum taurine; Uterine bleeding

Indexed keywords

CA 125 ANTIGEN; TAURINE;

ADULT; ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; LEIOMYOMA; METRORRHAGIA; PRIORITY JOURNAL; UTERUS BLEEDING;

EID: 84858984946     PISSN: None     EISSN: 18742912     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Koss L, Cramer D, Ferenczy A. Recent advances in endometrial neoplasia. Acta Cytol 1980; 24: 478-93.
2. Daniilidis A, Dinas K. Long term health consequences of polycystic ovarian syndrome: a review analysis. Hippokratia 2009; 13(2): 90-2.
3. Grin W, Grunberger W. A significant correlation between melatonin deficiency and endometrial cancer. Gynecol Obstet Invest 1998; 45: 62-5.
4. Van Doom H, Opmeer BC, Kooi GS, Ewing-Graham PC, Kruitwagen RF, Mol BW. Value of cervical cytology in diagnosing endometrial carcinoma in women with postmenopausal bleeding. Acta Cytol 2009; 53: 277-82.
5. Rice L, Jazaeri A, Shupnik M. Estrogen receptor mRNA splice variation in pre and post-menopausal human endometrium and endometrial carcinoma. Gynecol Oncol 1997; 65: 149-57.
6. Danforth K, Eliassen A, Tworoger S, et al. The association of plasma androgen levels with breast, ovarian, and endometrial cancer risk factors among postmenopausal women. Int J Cancer 2010; 126: 199-207.
7. Arias-Pulido H, Smith H, Joste N, et al. Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol 2009; 114: 480-5.
8. Bernischke K. The endometriom; In: Reproductive endocrinology. Yen SS, Jaffe RB, Eds. Saunders: Philadelphia 1986; pp. 385-405.
9. Mueck AO, Seeger H. Hormone therapy after endometrial cancer. Horm Res 2004; 62: 40-8.
10. Zamurovi M, Srbinovi P, Petrovi J, Zamurovi M, Srbinovi P, Petrovi J. Multiple endometrial polyps in patient undergoing longterm gestagen therapy. Srp Arh Celok Lek 2005; 133: 438-40.
11. Elmasry K, Davies AJ, Evans DG, Seif MN, Reynolds K. Strategies: for endometrial screening in the Lynch syndrome population: a patient acceptability study. Fam Cancer 2009; 8: 431-9.
12. Huxitable, R. Physiological action of taurine. Physiol Rev 1992; 72: 101-63.
13. Oriyanhan W, Yamazaki K, Miwa S, Takaba K, Ikeda T, Komeda M. Taurine prevents myocardial ischemia/reperfusion-induced oxidative stress and apoptosis in prolonged hypothermic rat heart preservation. Heart Vessels 2005; 20(6): 278-85.
14. Fontana M, Pecci L, Duprè S, Cavallini D. Antioxidant properties of sulfinates: protective effect of hypotaurine on peroxynitritedependent damage. Neurochem Res 2004; 29(1): 111-6.
15. Ortega JA, Ortega JM, Julian D. Hypotaurine and sulfhydrylcontaining antioxidants reduce H2S toxicity in erythrocytes from a marine invertebrate. J Exp Biol 2008; 211(Pt 24): 3816-25.
16. El-Agousa I, El-nashar D, Eissa S, Sharoud M. Possible ameliorative effect of antioxidant (Taurine) in pregnant toxemic female Rats. Open Hypertens J 2009; 2: 1-15.
17. El Agouza I, Eissa S, El Nashar D. The possibility of antiangiogenetic effect of taurine in hepatocellular carcinoma induced in rats treated with diethylnitrosamin (DENA). Cancer Res J 2010 (In press).
18. Okamoto K, Sugie S, Ohnishi M, et al. Chemopreventive effects of taurine on diethylnitrosamine and Phenobarbital - induced hepatocarcinogenesis in male F344 rats. Jpn J Cancer Res 1996; 87: 30-6.
19. You J, Chang K. Taurin protects the liver against lipid proxidation and membrane disintegration during rat hepatocarcinogenesis. Adv Exp Med Biol 1998; 442: 105-12.
20. Liang J, Zhang L, Yang Y, et al. Observation of promotion effect taurine on hepatic stellate cell's apoptosis in rat hepatic fibrosis model. Sichuan Da Xue Xue Bao Yi Xue Ban 2005; 36: 365-7.
21. Warskulat U, Borsch E, Reinehr R. et al. Chronic liver disease is triggered by taurine transporter knockout in the mouse. FASEB J 2006; 20: 574-6.
22. Reddly B, Rao C, Rivenson A, Kelloff G. Chemoprevention of colon carcinogenesis by organosulfur compoubds. Cancer Res 1993; 53: 3493-8.
23. Shekels L, Beste J, Ho S. Tauroursodeoxy cholic acid protects in vitro models of human colonic cancer cells from cytotoxic effects of hydrophobic bile acid. J Lab Clin Med 1996; 127: 57-66.
24. Cheng K, Xie G, Raufman J. Matrix metalloproteinase-7-catalyzed release of HB-EGF mediates deoxycholyltaurine-induced proliferation of a human colon cancer cell line. Biochem Pharmacol 2007; 73: 1001-12.
25. Monoson J, Ramesy P, Donohue J. Taurolidine inhibits tumor necrosis factor (TNF) toxicity - New evidence of TNF and endotoxin synergy. Eur J Surg Oncol 1993; 19: 226-31.
26. Jacobi C, Menenakos C, Braumann C. Taurolidine-a new drug with anti-tumor and anti-angiogenic effects. Anticancer Drugs 2005; 16: 917-21.
27. Rodak R, Kubota H, Ishihara H. Induction of reactive oxygen intermediates-dependent programmed cell death in human malignant ex vivo glioma cells and inhibition of the vascular endothelial growth factor production by taurolidine. J Neurosurg 2005; 102: 1055-68.
28. Moreno A, Rey M, Montane JM, Alonso J, Arus C. 1H NMR spectroscopy of colon tumors and normal mucosal biopsies; elevated taurine levels and reduced polyethyleneglycol absorption in tumors may have diagnostic significance. NMR Biomed 1993; 6(2): 111-8.
29. Chromik AM, Daigeler A, Hilgert C, et al. Synergistic effects in apoptosis induction by taurolidine and TRAIL in HCT-15 colon carcinoma cells. J Invest Surg 2007; 20 (6): 339-48.
30. Opitz I, Sigrist B, Hillinger S, et al. Taurolidine and povidoneiodine induce different types of cell death in malignant pleural. Lung Cancer 2007; 56: 327-36.
31. Finnegan N, Toomey D, Condron C, et al. Potentiation of the therapeutic index of IL-2 immunotherapy by combination with taurine in a syngeneic murine tumor model. Irish J Med Sci 2002; 170: 223-7.
32. El Agouza I, Eissa S, El Nashar D. The possibility of using serum taurine as early marker in patients with hepatocellular carcinoma. Cancer Res J 2010 (In press).
33. El Agouza I, Eissa S, El Nashar D, Abd El Hameed O. Taurine: a novel tumer marker for enhanced detection of breast cancer among female patients. Angiogenesis J 2011; [Epub ahead pf print].
34. Heinrikson R, Meredith S. Amino acid analysis by RP - HPLC: Precolumn derivatization with phenylisothiocyanate. Anal Biolchem 1984; 11: 136-65.
35. Ishigami T, Fujita T, Simbula G. Regulatory effects of senescence marker protein 30 on the proliferation of hepatocytes. Pathol Int 2001; 51: 491-7.
36. El-Idrissi D, Miloud K, Belgacem S. Constraints and obstacles to social health protection in the Maghreb: the cases of Algeria and Morocco. Bull World Health Organ 2008; 86: 902-4.
37. Folkman J, Kalluri R. Tumor Angiogenesis. In: Kufe DW, Bast RC, Hart WN, et al. Eds. Holland-Feri. Cancer Medicin. 6th ed. London: BC Decker Inc Hamolton 2003; pp. 161-94.
38. Folkman J, Kalluri R. Tumor Angiogenesis. In Kufe DW, Bast RC, Hart WN, et al. Eds. Holland-Feri. Cancer Medicin. On line 7th ed. London: BC Decker Inc Hamolton 2006; pp. 161-94.
39. Gjedds S, Mouridsen H, Madsen E, et al. Phase I study of tauromustine administered in a weekly schedule. Eur J Cancer 1993; 29: 1901-2.
40. Singh G, Graffner HO, Milsom JW, Chaudry IH. Tauromustine is more effective than conventional chemotherapy in the treatment of colonic tumors. Dis Colon Rectum 1993; 36: 394-9.
41. Hill S, Pollard L, Bibby M. Sequence dependet activity of 5-fluorouracil plus tauromustin in a transplantable well - differentiated murine colon adenocarcinoma. Anticancer Res1992; 12: 2169-75.
42. Bibby M, Loadman P, Al-Ghabban A, Double J. Influence of hydralazine on the pharmacokinetics of taurmustine in mice. Br J Cancer 1992; 65: 347-50.
43. Ross G, El-Hag I, Christensson P, Stenran U. The antitumor effect of a noval nitrosourea tauromustin. At iv administration in rat -cure of hepatoma. Anticancer Res 1991; 11: 1763-6.
44. Gatzemeier U, Dring P, Edler L, et al. Chemotherapy with tauromustine in advanced non-small cell lung cancer. Onkologie 1990; 13: 186-8.
45. Tabassum H, Parvez S, Rehman H, Dev Banerjee B, Siemen D, Raisuddin S. Nephrotoxicity and its prevention by taurine in tamoxifen induced oxidative stress in mice. Hum Exp Toxicol 2007; 26: 509-18.
46. Kinami Y, Ashida Y, Gotoda H, Seto K, Kojima Y, Takashima S. Promoting effects of bill acid load on the occurrance of cholangio carcinoma induced by diisopropanol nitrosamine in hamster. Oncology 1993; 50: 46-51.
47. Jacobi C, Ordemann J, Boham B, Zieren H, Sabat R, Muller J. Inhibition of peritoneal tumor cell growth and implantation in laproscopic surgery in a rat model. Am J Surg 1997; 17: 359-63.
48. Jacobi C, Menenakos C, Braumann C. Taurolidine-a new drug with anti-tumor and anti-angiogenic effects. Anticancer Drugs 2005; 16: 917-21.
49. Bhuvarahamurthy V, Balasubramanian N, Govindasamy S. Effect of radiotherapy and chemorodiotherapy on circulating antioxidant system of human uterine cervical carcinoma. Mol Cell Biochem 1996; 158: 17-23.
50. Kullak-Ublick G, Glasa J, Boker C. Chlorambucil - taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinoma. Gastroenterology 1997; 113: 1295-305.
51. Luther T, Hammerman P, Rahmaou I. Evidence for an ATP - dependent bile acid transport protein other than the canalicular liver ecto - ATPase in rats. Gastroenterology 1997; 113: 249-54.
52. Warskulat U, Wettstein M, Haussinger D. Osmoregulated taurin transport in H4 IIE hepatoma cells and perfused rate liver. Bichom J 1997; 321: 683-90.
53. Cheryl L, Claire W, Reynolds R, Mack T. Prevention of cervix cancer. Crit Rev Oncol 2000; 3:169-85.
54. th ed. New York: Lippincott Company 1992; vol. II: pp. 253-1302.
55. Hortobagyi GN, de la Garza Salazar J, Pritchard K: The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 2005; 6: 391-401.
56. Duk J, Alders J, Fleuren G, Bruijin A. CA-125: a useful marker in endometrial cancer. Am J Obstet Gynecol 1986; 155: 1097-2000.
57. Maurie M, Massimo F, Liu P, Edward H, David A. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. Gynecol Oncol 2006; 103: 195-8.
58. Pastner B, Mann W, Cohen H, Loesch M. Predictive value of preoperative serum CA.125 levels in clinically localized and advanced Carcinoma. Am J Obstet Gynecol 1988; 158: 399-402.
59. Deborah J, Dotters M. Preoperative CA-125 in endometrial cancer: it is useful? Am J Obstet Gynecol 2000; 182: 1328-34.
60. Eissa S, Shauman S. Tumor markers in gynecological neoplasia, In: Hand Book of tumor markers. 1st ed. Eissa S, Shoman S, Eds. Cairo, Egypt: Khattab Press 1995; pp. 66-75.
61. Eissa S, Shauman S. Tumor markers inselected organ: Tumor marker in breast neoplasm. Eissa S, Shauman S, Eds. londo: Tumor markers charman7 Hall 1998.
62. Eissa S. Tumor pathology in Nafussi A. Tumor diagnosis practical approach and pattern analysis. London: Hodder Arnold 2005; pp. 1215-60.
63. Jacobs I, Bast R. The CA - 125 tumor associated antigen, a review of the literature. Clin Rev 1998; 4: 1-12.
64. Van haaften-day C, Shen Y, Xu F. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 2001; 92: 2837-44.
65. Kurman R, Kaminski P, Norris H. The behavior of endometrial hyperplasia. Cancer 1985; 56: 453-56.
66. Jiang X, Yang M, Morris C, et al. High field protein NMR investigation of the metabolic profiles of multidrug - sensitive and resistant leukaemic cell lines: evidence for diminished taurine levels in multidrug resitant cells. Free Radic Res Commun 1993; 19: 355-69.
67. Hyung S, Young-Nam C, Chaekyun K. Taurine chloramines inhibits PMA-stimulated superoxide production in human neutrophils perhaps by inhibiting phosphorylation and translocation of P47phox. J Int Immunopharmacol 2006; 6: 1434-40.
68. Kanghyun J, Youna L, Deakyu C, et al. An anti-inflammatory mechanism of taurine conjugated 5-aminosalicylic acid against experimental colitis: taurine chloramine potentiates inhibitory effect of 5- aminosalicylic acid on 1L-1-mediated NFkB activation. J Eur J Pharmacol 2009; 618: 91-7.
69. Sonnewald U, Isern E, Gribbestad I, Unsgard G. UDP-N- acetylhexosamines and hypoturine in human glioplastoma normal brain tissue and cell cultures. 1H/NMR spectroscopy study. Anticancer Res 1994; 14: 793-8.